Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1135-41. doi: 10.1016/j.ijrobp.2009.09.037. Epub 2010 Mar 16.
We designed this study to determine which patients have a high risk of supraclavicular node recurrence in N1 breast cancer previously treated with surgery but not having received supraclavicular radiation therapy (SCRT) and to identify which patients needed SCRT.
We performed a retrospective review of 448 pathologic N1 breast cancer patients treated with mastectomy or breast-conserving treatment, but without SCRT, between 1994 and 2003. Mastectomy was performed in 302 patients (67.4%). The median number of axillary nodes dissected was 17 (range, 5-53). Systemic chemotherapy was administered in 443 patients (98.9%), and 144 patients received radiation after breast-conserving surgery. The median follow-up was 88 months (range, 15-170 months).
At follow-up, the treatment failed in 101 patients (22.5%), and 39 patients (8.7%) had supraclavicular node recurrence. Prognostic factors in supraclavicular node recurrence included lymphovascular invasion (p < 0.0001), extracapsular extension (p < 0.0001), the number of involved axillary nodes (p = 0.0003), and the level of involved axillary nodes (p = 0.012) in univariate and multivariate analyses. The total number of prognostic factors correlated well with supraclavicular node recurrence. In the analysis of 5-year supraclavicular node recurrence-free survival, patients with two or more factors showed a significantly higher recurrence rate than did patients with fewer than two factors (96.8% and 72.9%, respectively; p < 0.0001).
The prognostic factors associated with supraclavicular node recurrence were lymphovascular invasion, extracapsular extension, and the number and level of involved axillary nodes. Patients with two or more prognostic factors might benefit from SCRT.
本研究旨在确定哪些接受过手术治疗但未接受锁骨上放射治疗(SCRT)的 N1 期乳腺癌患者具有锁骨上淋巴结复发的高风险,并确定哪些患者需要接受 SCRT。
我们对 1994 年至 2003 年间接受乳房切除术或保乳治疗但未接受 SCRT 的 448 例病理 N1 期乳腺癌患者进行了回顾性分析。302 例患者(67.4%)接受了乳房切除术。腋窝淋巴结清扫的中位数为 17 个(范围,5-53 个)。443 例患者接受了全身化疗,144 例患者在保乳手术后接受了放疗。中位随访时间为 88 个月(范围,15-170 个月)。
随访时,101 例(22.5%)患者治疗失败,39 例(8.7%)患者锁骨上淋巴结复发。锁骨上淋巴结复发的预后因素包括脉管侵犯(p<0.0001)、囊外扩散(p<0.0001)、受累腋窝淋巴结数量(p=0.0003)和受累腋窝淋巴结水平(p=0.012),在单因素和多因素分析中均有统计学意义。总预后因素与锁骨上淋巴结复发密切相关。在 5 年锁骨上淋巴结无复发生存率分析中,具有 2 个或更多因素的患者复发率明显高于具有 2 个以下因素的患者(分别为 96.8%和 72.9%;p<0.0001)。
与锁骨上淋巴结复发相关的预后因素包括脉管侵犯、囊外扩散以及受累腋窝淋巴结的数量和水平。具有 2 个或更多预后因素的患者可能受益于 SCRT。